Brain-inspired neuromorphic computing offers significant potential for efficient and adaptive computational platforms. Emerging ferroelectric and antiferroelectric HfZrO_<i>x</i> devices provide key roles in convolutional neural network (CNN) and spiking neural network (SNN) computing with unique polarization switching characteristics. Here, we present ferroelectric/antiferroelectric HfZrO_<i>x</i> devices to realize functions of artificial synapse/neurons by element doping engineering. The HfZrO_<i>x</i>-based ferroelectric and antiferroelectric devices exhibit excellent endurance characteristics of 1 × 10⁹ cycles. Based on the non-volatile polarization switching and spontaneous depolarization nature of ferroelectric and antiferroelectric devices, integrate-and-fire behaviors were constructed for neuromorphic computing. For the first time, a complementary ferroelectric/antiferroelectric HfZrO_<i>x</i> artificial synapse/neuron-based hybrid CNN-SNN framework was constructed for energy-efficient cardiac magnetic resonance imaging (MRI) classification. The hybrid neural network breaks the limitation of pure SNN in 3D image recognition and improves the accuracy from 82.3 to 92.7% compared to pure CNN, highlighting the potential of composition-engineered ferroelectric materials to implement high-efficiency neuromorphic computing.

Quantitative imaging (QI) holds significant potential across diverse clinical applications. For clinical translation of QI, rigorous evaluation on clinically relevant tasks is essential. This article outlines 4 emerging evaluation frameworks, including virtual imaging trials, evaluation with clinical data in the absence of ground truth, evaluation for joint detection and quantification tasks, and evaluation of QI methods that output multidimensional outputs. These frameworks are presented in the context of recent advancements in PET, such as long axial field of view PET and the development of artificial intelligence algorithms for PET. We conclude by discussing future research directions for evaluating QI methods.

Neonatal Encephalopathy (NE) from presumed hypoxic-ischemic encephalopathy (pHIE) is a leading cause of morbidity and mortality in infants worldwide. Recent advancements in HIE research have introduced promising tools for improved screening of high-risk infants, time to diagnosis, and accuracy of assessment of neurologic injury to guide management and predict outcomes, some of which integrate artificial intelligence (AI) and machine learning (ML). This review begins with an overview of AI/ML before examining emerging prognostic approaches for predicting outcomes in pHIE. It explores various modalities including placental and fetal biomarkers, gene expression, electroencephalography, brain magnetic resonance imaging and other advanced neuroimaging techniques, clinical video assessment tools, and transcranial magnetic stimulation paired with electromyography. Each of these approaches may come to play a crucial role in predicting outcomes in pHIE. We also discuss the application of AI/ML to enhance these emerging prognostic tools. While further validation is needed for widespread clinical adoption, these tools and their multimodal integration hold the potential to better leverage neuroplasticity windows of affected infants. IMPACT: This article provides an overview of placental pathology, biomarkers, gene expression, electroencephalography, motor assessments, brain imaging, and transcranial magnetic stimulation tools for long-term neurodevelopmental outcome prediction following neonatal encephalopathy, that lend themselves to augmentation by artificial intelligence/machine learning (AI/ML). Emerging AI/ML tools may create opportunities for enhanced prognostication through multimodal analyses.

Parkinson's disease (PD) is a progressive neurodegenerative disorder that affects both motor and non-motor functions, primarily due to the gradual loss of dopaminergic neurons in the substantia nigra. Traditional diagnostic methods largely depend on clinical symptom evaluation, which often leads to delays in detection and treatment. However, in recent years, artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL), have emerged as groundbreaking techniques for the diagnosis and management of PD. This review explores the emergent role of AI-driven techniques in early disease detection, continuous monitoring, and the development of personalized treatment strategies. Advanced AI applications, including medical imaging analysis, speech pattern recognition, gait assessment, and the identification of digital biomarkers, have shown remarkable potential in improving diagnostic accuracy and patient care. Additionally, AI-driven telemedicine solutions enable remote and real-time disease monitoring, addressing challenges related to accessibility and early intervention. Despite these promising advancements, several hurdles remain, such as concerns over data privacy, the interpretability of AI models, and the need for rigorous validation before clinical implementation. With PD cases expected to rise significantly by 2030, further research and interdisciplinary collaboration are crucial to refining AI technologies and ensuring their reliability in medical practice. By bridging the gap between technology and neurology, AI has the potential to revolutionize PD management, paving the way for precision medicine and better patient outcomes.

Nano-sized drug delivery systems have emerged as a more effective, versatile means for improving cancer treatment. However, the complexity of drug delivery to cancer involves intricate interactions between physiological and physicochemical processes across various temporal and spatial scales. Relying solely on experimental methods for developing and clinically translating nano-sized drug delivery systems is economically unfeasible. Multiphysics models, acting as open systems, offer a viable approach by allowing control over the individual and combined effects of various influencing factors on drug delivery outcomes. This provides an effective pathway for developing, optimising, and applying nano-sized drug delivery systems. These models are specifically designed to uncover the underlying mechanisms of drug delivery and to optimise effective delivery strategies. This review outlines the diverse applications of multiphysics simulations in advancing nanos-sized drug delivery systems for cancer treatment. The methods to develop these models and the integration of emerging technologies (i.e., medical imaging and artificial intelligence) are also addressed towards digital twins for personalised clinical translation of cancer nanomedicine. Multiphysics modelling tools are expected to become a powerful technology, expanding the scope of nano-sized drug delivery systems, thereby greatly enhancing cancer treatment outcomes and offering promising prospects for more effective patient care.

Breast cancer is the most prevalent malignancy in women, with the status of axillary lymph nodes being a pivotal factor in treatment decision-making and prognostic evaluation. With the integration of deep learning algorithms, radiomics has become a transformative tool with increasingly extensive applications across multimodality, particularly in oncological imaging. Recent studies of radiomics and deep learning have demonstrated considerable potential for noninvasive diagnosis and prediction in breast cancer through multimodalities (mammography, ultrasonography, MRI and PET/CT), specifically for predicting axillary lymph node status. Although significant progress has been achieved in radiomics-based prediction of axillary lymph node metastasis in breast cancer, several methodological and technical challenges remain to be addressed. The comprehensive review incorporates a detailed analysis of radiomics workflow and model construction strategies. The objective of this review is to synthesize and evaluate current research findings, thereby providing valuable references for precision diagnosis and assessment of axillary lymph node metastasis in breast cancer, while promoting development and advancement in this evolving field.

The integration of artificial intelligence (AI) into radiology has significantly improved diagnostic accuracy and workflow efficiency. Multimodal large language models (MLLMs), which combine natural language processing (NLP) and computer vision techniques, hold the potential to further revolutionize medical image analysis. Despite these advances, their widespread clinical adoption of MLLMs remains limited by challenges such as data quality, interpretability, ethical and regulatory compliance- including adherence to frameworks like the General Data Protection Regulation (GDPR) - computational demands, and generalizability across diverse patient populations. Addressing these interconnected challenges presents opportunities to enhance MLLM performance and reliability. Priorities for future research include improving model transparency, safeguarding data privacy through federated learning, optimizing multimodal fusion strategies, and establishing standardized evaluation frameworks. By overcoming these barriers, MLLMs can become essential tools in radiology, supporting clinical decision-making, and improving patient outcomes.

Accurate prognostication and personalized treatment selection remain major challenges in kidney cancer. This consensus initiative aimed to provide actionable expert guidance on the development and clinical integration of prognostic and predictive biomarkers and risk stratification tools to improve patient care and guide future research. A modified Delphi method was employed to develop consensus statements among a multidisciplinary panel of experts in urologic oncology, medical oncology, radiation oncology, pathology, molecular biology, radiology, outcomes research, biostatistics, industry, and patient advocacy. Over 3 rounds, including an in-person meeting 20 initial statements were evaluated, refined, and voted on. Consensus was defined a priori as a median Likert score ≥8. Nineteen final consensus statements were endorsed. These span key domains including biomarker prioritization (favoring prognostic biomarkers), rigorous methodology for subgroup and predictive analyses, the development of multi-institutional prospective registries, incorporation of biomarkers in trial design, and improvements in data/biospecimen access. The panel also identified high-priority biomarker types (e.g., AI-based image analysis, ctDNA) for future research. This is the first consensus statement specifically focused on biomarker and risk model development for kidney cancer using a structured Delphi process. The recommendations emphasize the need for rigorous methodology, collaborative infrastructure, prospective data collection, and focus on clinically translatable biomarkers. The resulting framework is intended to guide researchers, cooperative groups, and stakeholders in advancing personalized care for patients with kidney cancer.

We aimed to review the role of functional imaging in cervical cancer to underscore its significance in the diagnosis and management of cervical cancer and in improving patient outcomes. This rapid literature review targeting the clinical guidelines for functional imaging in cervical cancer sourced literature from 2017 to 2023 using PubMed, Google Scholar, MEDLINE and Scopus. Keywords such as cervical cancer, cervical neoplasms, functional imaging, stag*, treatment response, monitor* and New Zealand or NZ were used with Boolean operators to maximise results. Emphasis was on English full research studies pertinent to New Zealand. The study quality of the reviewed articles was assessed using the Joanna Briggs Institute critical appraisal checklists. The search yielded a total of 21 papers after all duplicates and yields that did not meet the inclusion criteria were excluded. Only one paper was found to incorporate the New Zealand context. The papers reviewed yielded results that demonstrate the important role of functional imaging in cervical cancer diagnosis, staging and treatment response monitoring. Techniques such as dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), diffusion-weighted magnetic resonance imaging (DW-MRI), computed tomography perfusion (CTP) and positron emission tomography computed tomography (PET/CT) provide deep insights into tumour behaviour, facilitating personalised care. Integration of artificial intelligence in image analysis promises increased accuracy of these modalities. Functional imaging could play a significant role in a unified approach in New Zealand to improve patient outcomes for cervical cancer management. Therefore, this study advocates for New Zealand's medical sector to harness functional imaging's potential in cervical cancer management.

Epilepsy surgery efficacy is critically contingent upon the precise localization of the epileptogenic zone (EZ). However, conventional qualitative methods face challenges in achieving accurate localization, integrating multimodal data, and accounting for variations in clinical expertise among practitioners. With the rapid advancement of artificial intelligence and computing power, multimodal quantitative analysis has emerged as a pivotal approach for EZ localization. Nonetheless, no research team has thus far provided a systematic elaboration of this concept. This narrative review synthesizes recent advancements across four key dimensions: (1) seizure semiology quantification using deep learning and computer vision to analyze behavioral patterns; (2) structural neuroimaging leveraging high-field MRI, radiomics, and AI; (3) functional imaging integrating EEG-fMRI dynamics and PET biomarkers; and (4) electrophysiological quantification encompassing source localization, intracranial EEG, and network modeling. The convergence of these complementary approaches enables comprehensive characterization of epileptogenic networks across behavioral, structural, functional, and electrophysiological domains. Despite these advancements, clinical heterogeneity, limitations in algorithmic generalizability, and barriers to data sharing hinder translation into clinical practice. Future directions emphasize personalized modeling, federated learning, and cross-modal standardization to advance data-driven localization. This integrated paradigm holds promise for overcoming qualitative limitations, reducing medical costs, and improving seizure-free outcomes.